Clinical Report: Mechanisms of Immune Evasion in ER-Positive Breast Cancer

Overview

This study elucidates the complex interplay between epithelial-to-mesenchymal transition (EMT), endocrine treatment resistance, and immune evasion in estrogen receptor-positive (ER+) breast cancer. The findings suggest that reversing EMT may offer a novel therapeutic strategy to enhance treatment sensitivity and improve patient outcomes.

Background

Estrogen receptor-positive breast cancer is the most prevalent subtype, representing approximately 80% of cases. Despite advancements in targeted therapies, resistance remains a significant challenge, particularly in advanced stages. Understanding the mechanisms of resistance and immune evasion is crucial for developing effective treatment strategies.

Data Highlights

No numerical data or trial data presented in the source material.

Key Findings

• Resistance to tamoxifen in ER+ breast cancer is linked to EMT regulators like ZEB1 and SLUG.
• Acquired resistance may be associated with reduced ERα levels and increased PD-L1 expression.
• EMT, resistance, and immune evasion are interconnected drivers of tumor adaptation.
• Mesenchymal-like groups exhibit significantly poorer survival outcomes.
• Combination therapies targeting chemoresistance and immune suppression may enhance treatment efficacy.

Clinical Implications

Clinicians should consider the role of EMT and immune evasion in treatment-resistant ER+ breast cancer. Strategies aimed at reversing EMT may improve therapeutic responses and patient survival. Ongoing assessment of tumor phenotypes can guide personalized treatment approaches.

Conclusion

The integration of regulatory modeling and patient data provides insights into the mechanisms of resistance in ER+ breast cancer, highlighting potential avenues for therapeutic intervention.

References

1. Endogenous Hormones Breast Cancer Collaborative Group, Archives of Toxicology, 2002 -- Impact of Breast Cancer Risk Factors on Cellular Proliferation and DNA Damage in Human Mammary Gland Tissues
2. Cooper et al., Archives of Toxicology, 2016 -- Analysis of Information-Dependent Enrichment Uncovers Temporal Transcriptional Regulation in the Estrogen Toxicity Pathway
3. Stephens et al., The ASCO Post, 2023 -- Receptor Status Among Patients With Invasive Breast Cancer: What’s Missing?
4. The ASCO Post — New Computational Tool May Predict Immunotherapy Outcomes in Patients With Metastatic Breast Cancer
5. NCCN 2026 Breast Cancer Congress_Neo-Adj
6. Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update
7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)